April 15th 2020EP. 1: An Overview of PH and PAH
April 15th 2020EP. 2: Considering the Economic Burden of PH and PAH
April 15th 2020EP. 3: Identifying Subpopulations of PH and PAH
April 15th 2020EP. 4: PH and PAH: An Overview of Treatment Options and Coverage
April 15th 2020EP. 5: PH and PAH: Mechanisms of Action of Common Treatment Pathway
April 15th 2020EP. 6: Oral, Parenteral, and Inhaled Agents in PH and PAH
April 15th 2020EP. 7: Identifying Connective Tissue Disease–Associated PAH
April 15th 2020EP. 8: CTD-PAH: Overview of Treatment Strategies
April 15th 2020EP. 9: Considering Therapy Based on PH and PAH Subpopulations
April 15th 2020EP. 10: Treatment for PH and PAH: Factors That Inform Coverage
April 15th 2020EP. 11: CTD-PAH: Adjusting Treatment Based on Patient Factors
April 15th 2020EP. 12: Identifying Portopulmonary Hypertension
April 15th 2020EP. 13: POPH: Challenges and Treatment Options
April 15th 2020EP. 14: Complexity of Chronic Thromboembolic Pulmonary Hypertension
April 15th 2020EP. 15: Optimal Management of CTEPH
April 15th 2020EP. 16: PH and PAH: Where and From Whom Are Patients Receiving Care
April 15th 2020EP. 17: PH and PAH: Care Coordination From the Payer Perspective
April 15th 2020EP. 18: PH and PAH: Defining Barriers and Gaps in Care
April 15th 2020EP. 19: The Evolving Treatment Landscape of PH and PAH
